Over the course of the study 211 patients received treatment.
• Patients infected with genotype 1: 98 percent of previously untreated patients had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 1: 98 percent of previously treated patients who did not have a sustained virologic response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 2: 92 percent had a sustained virologic response at week 12.
• Patients infected with genotype 3: 89 percent had a sustained virologic response at week 12.
• The most common adverse events included nausea, headache and fatigue.
More Articles on Gastroenterology:
EndoChoice Launches Study to Demonstrate Clinical Significance of Fuse Endoscopy System
5 Current Treatments for Ulcerative Colitis
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
